Immunomedics mulls veltuzumab options as Takeda ends deal amid dispute
This article was originally published in Scrip
Executive Summary
The US firm Immunomedics has regained all global rights to veltuzumab after Takeda terminated a licensing deal for the anti-CD20 monoclonal antibody.